West Nile virus and plasma-derived medicinal products - Scientific guideline

HumanScientific guidelines

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

This document addresses the viral safety of plasma-derived medicinal products with respect to West-Nile virus (WNV).

Keywords: Viral safety, plasma-derived medicinal products, West-Nile virus

Current effective version

CPMP position statement on West Nile virus and plasma-derived medicinal products

Adopted Reference Number: EMEA/CPMP/BWP/3752/03/adopted Legal effective date: 25/07/2003

English (EN) (134.87 KB - PDF)

First published: 25/07/2003 Last updated: 25/07/2003